# US 11,433,118 B2 · Long-acting VEGF inhibitors for intraocular neovascularization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,118 B2
- Document ID: US11433118B2
- Status: Granted
- Kind: B2
- Application number: 17/522,318
- Filed: 2021-11-09
- Published: 2022-03-24
- Granted: 2022-09-06
- Earliest claimed: 2019-11-25
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Napoleone Ferrara
- Web page: https://patentgrep.com/patent/US11433118B2

## CPC

- A61K 38/179: {for growth factors; for growth regulators}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 39/001109: {Vascular endothelial growth factor receptors [VEGFR]}
- A61P 27/02: Ophthalmic agents
- C07K 14/71: for growth factors; for growth regulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1.

## Claims

### Claim 1

A method of treating a VEGF related condition in an eye of a subject comprising: administering to the eye an anti-VEGF agent consisting of the amino acid residues 27 to 459 of SEQ ID NO: 3.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering comprises an intravitreal injection.

### Claim 3 (depends on 1)

The method of claim 1, wherein the VEGF related condition comprises neovascularization.

### Claim 4 (depends on 3)

The method of claim 3, wherein the neovascularization is choroidal neovascularization.

### Claim 5 (depends on 3)

The method of claim 3, wherein the neovascularization is retinal neovascularization.

### Claim 6 (depends on 3)

The method of claim 3, wherein the VEGF related condition is age-related macular degeneration.